BAAM
MRVI icon

Baker Avenue Asset Management’s Maravai LifeSciences MRVI Stock Holding History

Baker Avenue Asset Management’s Portfolio MRVI Stock Details MRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2023
Q3 		– Sell
-18
Closed -$224 – 1668
2023
Q2 		$224 Buy
+18
New +$243 ﹤0.01% 1561

Other funds holding MRVI

GL
GTCR LLC Chicago, Illinois $3.78B AUM 27.82% 1-Year Est. Return
Thrivent Financial for Lutherans
Thrivent Financial for Lutherans Minneapolis, Minnesota $52.5B AUM 27.12% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
Massachusetts Financial Services
Massachusetts Financial Services Boston, Massachusetts $298B AUM 21.96% 1-Year Est. Return
1WCM
12 West Capital Management New York $592M AUM 40.75% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Mackenzie Financial
Mackenzie Financial Toronto Ontario, Ontario, Canada $83.3B AUM 31.19% 1-Year Est. Return
Millennium Management
Millennium Management New York $240B AUM 35.51% 1-Year Est. Return
B
Braidwell Stamford, Connecticut $3B AUM 46.72% 1-Year Est. Return
ClearBridge Investments
ClearBridge Investments New York $115B AUM 24.78% 1-Year Est. Return

Baker Avenue Asset Management's MRVI Position: Q3 2023 in Review

Baker Avenue Asset Management sold out of Maravai LifeSciences (MRVI) in Q3 2023, closing a stake of 18 shares — an estimated $224 sold.

Baker Avenue Asset Management first reported a position in MRVI in Q2 2023 and held it in 1 quarter. The position peaked at $224 in Q2 2023. 204 funds tracked by Wall St. Rank hold MRVI as of Q3 2023.

  • Baker Avenue Asset Management reported no remaining Maravai LifeSciences position as of Q3 2023 after selling out during the quarter.
  • Baker Avenue Asset Management sold 18 Maravai LifeSciences shares in Q3 2023, an estimated $224.
  • Baker Avenue Asset Management first reported a position in Maravai LifeSciences in Q2 2023 and held it in 1 quarter.
  • Baker Avenue Asset Management's Maravai LifeSciences position peaked at $224 in Q2 2023.
  • 204 funds tracked by Wall St. Rank held Maravai LifeSciences as of Q3 2023.

Based on Baker Avenue Asset Management's 13F filing for Q3 2023, filed 15 Nov 2023.